Our latest articles
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
Spending heavily on buybacks and dividends does not mean sector-leading share price performance, Evaluate Vantage finds.
The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.
Bristol Myers Squibb has spent the most on M&A, R&D and licensing since 2017, and Eli Lilly the least. Guess which strategy is working best.
Positive data result in positive share price movements – something of a novelty in the current market.
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Trading well below cash hasn’t stopped Cullinan from extracting more from Otsuka, when a low-ball buyout might have been on the cards.
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
After the latest roxadustat clanger a phase 3 interim analysis in pancreatic cancer becomes even more important for Fibrogen.
Biohaven looks to have timed its exit well, giving investors more reason to cheer the $11.6bn buyout.